RETRACTED: Silencing of Ether à go-go 1 by shRNA inhibits osteosarcoma growth and cell cycle progression

Area of Science:

• Molecular Biology
• Oncology
• Channelopathies

Background:

• The voltage-dependent potassium channel (Kv) family member, Ether à go-go 1 (Eag1), is implicated in cell proliferation and tumorigenesis.
• The therapeutic role of Eag1 in osteosarcoma has not been fully explored.

Purpose of the Study:

• To investigate the therapeutic potential of targeting the Eag1 channel in human osteosarcoma cells.

Main Methods:

• A recombinant adenovirus carrying short hairpin RNA (shRNA) against Eag1 was used to silence Eag1 expression in MG-63 osteosarcoma cells.
• Cell proliferation, colony formation, and cell cycle progression were assessed.
• In vivo studies utilized a xenograft nude mice model to evaluate tumor growth inhibition.
• Expression levels of cyclin D1 and E were measured.

Main Results:

• Eag1 silencing via shRNA significantly inhibited MG-63 cell proliferation and colony formation.
• Eag1 knockdown induced G1 phase arrest in the cell cycle.
• In vivo experiments demonstrated that Eag1-shRNA suppressed osteosarcoma growth in mice.
• The expression of cyclin D1 and E was notably reduced following Eag1 inhibition.

Conclusions:

• The Eag1 channel is essential for osteosarcoma cell proliferation and cell cycle regulation.
• Targeting Eag1 represents a promising therapeutic strategy for osteosarcoma treatment.